ストックスクリーナーアプリを入手
44.23
2.12%
0.92
アフターアワーズ：
44.32
0.09
+0.20%
前日終値:
$43.31
開ける：
$43.61
24時間の取引高:
18.62M
Relative Volume:
1.29
時価総額：
$90.01B
収益：
$47.70B
当期純損益:
$5.05B
株価収益率:
17.83
EPS:
2.48
ネットキャッシュフロー:
$14.58B
1週間 パフォーマンス:
-8.67%
1か月 パフォーマンス:
-6.90%
6か月 パフォーマンス:
-24.97%
1年 パフォーマンス:
-8.18%
1日の値動き範囲:
$43.57
$44.45
1週間の範囲:
$42.96
$48.46
52週間の値動き範囲:
$42.96
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
名前
Bristol Myers Squibb Co
セクター
電話
(609) 252-4621
住所
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
BMY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
44.23 | 88.14B | 47.70B | 5.05B | 14.58B | 2.48 |
|
LLY
Lilly Eli Co
|
762.33 | 664.39B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
167.33 | 396.75B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
195.22 | 333.89B | 58.33B | 3.76B | 15.39B | 2.10 |
|
NVS
Novartis Ag Adr
|
115.30 | 220.18B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
79.29 | 196.16B | 63.62B | 16.41B | 17.04B | 6.49 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 開始されました | Piper Sandler | Overweight |
| 2024-12-16 | アップグレード | Jefferies | Hold → Buy |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-13 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-07-29 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-03-11 | ダウングレード | Societe Generale | Buy → Hold |
| 2024-02-06 | ダウングレード | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-11-15 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-02 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | アップグレード | HSBC Securities | Reduce → Hold |
| 2023-10-27 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-07-10 | 開始されました | SVB Securities | Market Perform |
| 2023-06-28 | 開始されました | Daiwa Securities | Outperform |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-01-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 開始されました | Credit Suisse | Neutral |
| 2022-10-10 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
| 2022-06-03 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Underweight |
| 2021-12-17 | 開始されました | Goldman | Buy |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-01 | ダウングレード | Argus | Buy → Hold |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-04-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | アップグレード | Truist | Hold → Buy |
| 2020-11-16 | アップグレード | Societe Generale | Hold → Buy |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-11-06 | ダウングレード | Gabelli & Co | Buy → Hold |
| 2020-10-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-07-28 | 開始されました | Raymond James | Outperform |
| 2020-04-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | ダウングレード | Societe Generale | Buy → Hold |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-01-06 | 再開されました | Citigroup | Buy |
| 2019-12-13 | アップグレード | Argus | Hold → Buy |
| 2019-11-22 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-08-14 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-05-20 | ダウングレード | Argus | Buy → Hold |
| 2019-05-03 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 再開されました | JP Morgan | Overweight |
| 2019-01-15 | アップグレード | Societe Generale | Sell → Buy |
| 2018-10-22 | ダウングレード | Citigroup | Buy → Neutral |
すべてを表示
Bristol Myers Squibb Co (BMY) 最新ニュース
Bristol-Myers Squibb: Declines Have Gone Too Far (NYSE:BMY) - Seeking Alpha
Bristol-Myers Squibb (BMY) Gains FDA Nod for TYK2 Inhibitor Sotyktu - Insider Monkey
Bristol-Myers Squibb: No Respect For Blowout EarningsBuy The Richer Dividend Yields - Seeking Alpha
Bristol-Myers Squibb Company (NYSE:BMY) Q2 2025 Earnings Call Transcript - Insider Monkey
Cautious Hold Rating on Bristol-Myers Squibb Amid Strong Q2 Results and Future Challenges - TipRanks
Accel-KKR, Carlyle, Vistria target home care software; Bain Capital, Bristol Myers Squibb launch autoimmune biopharma biz - pehub.com
Testicular Cancer Market Analysis and Forecast Report 2025-2035 | Emerging Trends Highlight Shift Towards Immunotherapy in Testicular Cancer - GlobeNewswire Inc.
Bristol-Myers Squibb Co (BMY) Q2 2025 Earnings Call Highlights: Robust Growth and Strategic ... By GuruFocus - Investing.com Canada
Bristol-Myers Squibb Co (BMY) Q2 2025 Earnings Call Highlights: - GuruFocus
What are the technical indicators suggesting about Bristol Myers Squibb Company Equity RightAI Powered Review For 2025 - jammulinksnews.com
Beyond the Balance Sheet: What SWOT Reveals About Bristol-Myers Squibb Co (BMY) - GuruFocus
Bristol-Myers Squibb (BMY) Sees Healthy Momentum in Growth Portfolio in Q2 2025 - Insider Monkey
BRISTOL MYERS SQUIBB CO SEC 10-Q Report - TradingView
Bristol Myers tops revenue expectations on strength of older drugs, shares fall By Reuters - Investing.com
Earnings call transcript: Bristol-Myers Squibb Q2 2025 sees earnings beat but stock dips - Investing.com Canada
Bristol Myers tops revenue expectations on strength of older drugs, shares fall - MarketScreener
BMS ups guidance, but its financial prospects fail to capture investor enthusiasm - FirstWord Pharma
Bristol Myers Beats on Q2 Earnings and Sales, Raises '25 Sales View - Yahoo Finance
Bristol Myers posts better-than-expected second quarter results on strength of top sellers - Bilyonaryo Business News
Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q2, Full-Year Sales Guidance is Optimistic - Yahoo Finance
Bristol Myers raises guidance as Q2 results beat forecasts - The Pharma Letter
Bristol Myers Squibb Q2 2025 Earnings Call Transcript - MarketBeat
Bristol Myers Cuts Earnings Outlook As Legacy Drugs Face Generic Erosion - Yahoo Finance
Is Wall Street Bullish or Bearish on Bristol-Myers Stock? - Yahoo Finance
Bristol-Myers Squibb stock hits 52-week low at 43.89 USD - Investing.com Nigeria
Bristol-Myers Squibb Co reports results for the quarter ended June 30Earnings Summary - TradingView
Bristol Myers Squibb's 2025 EPS Target Revisions: A Strategic Realignment for Long-Term Growth - AInvest
Bristol Myers Squibb (BMY) Q2 Earnings and Revenues Top Estimates - Yahoo Finance
Bristol Myers Squibb Cuts Full-Year Adjusted View, but Raises Revenue Expectations - The Wall Street Journal
Bristol-Myers Squibb Co Surpasses Revenue Estimates with $12.3 Billion, Non-GAAP EPS of $1.46 Exceeds Expectations - GuruFocus
Bristol-Myers Squibb shares rise as Q2 results boosted by growth portfolio - Investing.com Nigeria
Bristol-Myers Squibb Q2 2025 slides: Growth portfolio drives revenue, guidance raised - Investing.com Australia
Bristol-Myers Squibb earnings beat by $0.40, revenue topped estimates - Investing.com Nigeria
Latest Q2 2025 Financial Results: Bristol Myers Squibb Releases Earnings Report and Investor Call Details - Stock Titan
Multiple Sclerosis Clinical Trials Market Landscape Report 2025 Featuring Biogen, Novartis, Sanofi, Merck, Teva, Bayer, Roche, Bristol-Myers Squibb, Laboratory Corp of America, IQVIA - Yahoo Finance
Dow Falls Over 150 Points After Powell's Comments On Rate Cuts: Investor Sentiment Declines, But Fear Index Remains In 'Greed' Zone - Benzinga
Microsoft, Apple And 3 Stocks To Watch Heading Into Thursday - Benzinga
BioNTech Stock Jumps on Bristol Myers Squibb Cancer Drug Collaboration - MSN
Bristol Myers Squibb: A Stock with Potential Amid Challenges - AOL.com
Bristol-Myers Squibb (BMY) Gets a Hold from Cantor Fitzgerald - The Globe and Mail
Bristol-Myers Squibb (BMY) Q2 Earnings: What To Expect - Yahoo Finance
Bain leads $300M bet on biotech developing BMS drugs - Axios
Bristol Myers Squibb Spins Out Immunology Assets into New Company Backed by Bain Capital - PharmExec
Why Investors View Bristol‑Myers Squibb (BMY) as a Safe Dividend Stock for Income - Insider Monkey
Bain Capital, Bristol Myers Squibb launch biotech with $300M - The Business Journals
October 17th Options Now Available For Bristol Myers Squibb (BMY) - Nasdaq
Bristol-Myers Squibb stock unchanged as Cantor Fitzgerald maintains Neutral rating - Investing.com Nigeria
Bristol Myers, Bain Capital form new company to develop immunology drugs - Reuters
Technical Bounce Expected in Bristol Myers Squibb Company Equity Right Next WeekTrade Scanner With Buy Zone Alerts Flagged - metal.it
Bristol-Myers Squibb stock unchanged as Cantor Fitzgerald maintains Neutral rating By Investing.com - Investing.com South Africa
BMS and Bain Capital create new company - The Pharma Letter
Bristol Myers Squibb Co (BMY) 財務データ
収益
当期純利益
現金流量
EPS
2.43%
大文字化:
|
ボリューム (24 時間):